Compare JBLU & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBLU | VCEL |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2002 | 1996 |
| Metric | JBLU | VCEL |
|---|---|---|
| Price | $5.28 | $45.05 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $4.91 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 29.6M | 604.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.83 | ★ 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,062,000,000.00 | $276,259,000.00 |
| Revenue This Year | $12.11 | $19.40 |
| Revenue Next Year | $6.75 | $18.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $3.87 | $28.95 |
| 52 Week High | $6.46 | $48.75 |
| Indicator | JBLU | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 52.92 |
| Support Level | $4.54 | $44.56 |
| Resistance Level | $6.31 | $48.75 |
| Average True Range (ATR) | 0.30 | 1.66 |
| MACD | -0.09 | -0.63 |
| Stochastic Oscillator | 33.67 | 18.65 |
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.